HRP20120441T1 - Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a - Google Patents

Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a Download PDF

Info

Publication number
HRP20120441T1
HRP20120441T1 HRP20120441AT HRP20120441T HRP20120441T1 HR P20120441 T1 HRP20120441 T1 HR P20120441T1 HR P20120441A T HRP20120441A T HR P20120441AT HR P20120441 T HRP20120441 T HR P20120441T HR P20120441 T1 HRP20120441 T1 HR P20120441T1
Authority
HR
Croatia
Prior art keywords
mixture
amount
hpmc
weight
mixture according
Prior art date
Application number
HRP20120441AT
Other languages
English (en)
Croatian (hr)
Inventor
R. Brown Jonathan
Toale Helen
B. Dennis Andrew
Timmins Peter
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20120441T1 publication Critical patent/HRP20120441T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
HRP20120441AT 2008-09-04 2009-09-03 Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a HRP20120441T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9413108P 2008-09-04 2008-09-04
PCT/US2009/055820 WO2010028108A2 (en) 2008-09-04 2009-09-03 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor

Publications (1)

Publication Number Publication Date
HRP20120441T1 true HRP20120441T1 (hr) 2012-06-30

Family

ID=41726353

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120441AT HRP20120441T1 (hr) 2008-09-04 2009-09-03 Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a

Country Status (16)

Country Link
US (2) US20100056540A1 (enExample)
EP (1) EP2323633B1 (enExample)
JP (1) JP5638527B2 (enExample)
CN (1) CN102143739B (enExample)
AT (1) ATE550016T1 (enExample)
CA (1) CA2735008C (enExample)
CY (1) CY1112816T1 (enExample)
DK (1) DK2323633T3 (enExample)
ES (1) ES2383149T3 (enExample)
HR (1) HRP20120441T1 (enExample)
NL (1) NL301118I2 (enExample)
PL (1) PL2323633T3 (enExample)
PT (1) PT2323633E (enExample)
SI (1) SI2323633T1 (enExample)
SM (1) SMT201200029B (enExample)
WO (1) WO2010028108A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5124327A (en) * 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
JP2686215B2 (ja) * 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents

Also Published As

Publication number Publication date
CA2735008A1 (en) 2010-03-11
WO2010028108A2 (en) 2010-03-11
SMT201200029B (it) 2012-09-07
ES2383149T3 (es) 2012-06-18
PT2323633E (pt) 2012-05-29
CY1112816T1 (el) 2016-02-10
CN102143739A (zh) 2011-08-03
DK2323633T3 (da) 2012-07-09
NL301118I1 (enExample) 2021-07-23
US20150158891A1 (en) 2015-06-11
ATE550016T1 (de) 2012-04-15
PL2323633T3 (pl) 2012-08-31
JP2012502042A (ja) 2012-01-26
US20100056540A1 (en) 2010-03-04
EP2323633A2 (en) 2011-05-25
JP5638527B2 (ja) 2014-12-10
SI2323633T1 (sl) 2012-07-31
CA2735008C (en) 2016-11-29
CN102143739B (zh) 2014-12-17
WO2010028108A3 (en) 2010-09-02
NL301118I2 (nl) 2022-02-22
EP2323633B1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
MA32385B1 (fr) Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone
SG11201908101YA (en) Hepatitis b virus surface antigen inhibitor
BRPI0613499A8 (pt) formulação de comprimido farmacêutico de 1[(3-hidróxi-adamant-1-ilamino)-acetil]- pirrolidino-2(s)-carbonitrila de liberação modificada, comprimido em multicamada, comprimido farmacêutico e cápsula contendo a mesma, processo de produção da mesma, seu uso, processo de preparação de comprimido bem como forma de dosagem farmacêutica
ME02520B (me) Farmaceutske kompozicije
CY1113063T1 (el) Παραγωγα πουρινης για χρηση ως αγωνιστες των α2α υποδοχεων αδενοσινης
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
HRP20192026T1 (hr) Formulacija tableta od neratinib maleata
MA34013B1 (fr) Inhibiteurs du virus de l'hépatite c
JP2021095421A (ja) 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
RU2013121788A (ru) Ингибиторы репликации вич
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
BR112012009857A2 (pt) composições farmacêuticas sólidas contendo um inibidor de integrase
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
NZ599762A (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2007128086A3 (en) Novel viral replication inhibitor
JP2018527305A5 (enExample)
RU2012109614A (ru) Фармацевтические композиции, содержащие производные бисфосфоната и высокие дозы холекальциферола
JP2011502131A5 (enExample)
ES2404811T3 (es) Formulaciones farmacéuticas de olmesartán
RU2008136315A (ru) Композиции ситаксентана натрия
HRP20120441T1 (hr) Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a
YU92201A (sh) Derivati naftiridina, postupci za njihovo dobijanje, njihova upotreba i farmaceutske kompozicije koje ih uključuju
JP2008088189A5 (enExample)
HRP980074A2 (en) Pharmaceutical formulations in dry form for the oral administration of a cyclic quaternary ammonium compound
YU89701A (sh) Substituisani derivati purina kao inhibitori adhezije ćelije